Déficit de vitamina D y morbimortalidad en pacientes críticos pediátricos / Vitamin D deficiency and morbimortality in critically ill paediatric patients

Objetivos: Determinar la prevalencia y factores de riesgo del déficit de vitamina D (VDD) en una unidad de cuidados intensivos pediátricos (UCIP), así como su relación con la morbimortalidad durante el ingreso. Material y métodos: Estudio observacional prospectivo realizado en la UCIP de un hospital terciario en 2 fases: I: estudio de cohortes, y II: estudio de prevalencia. Se incluyó a 340 niños > 6 meses, excluyendo a aquellos con enfermedad renal crónica, trastornos paratiroideos y suplementación con vitamina D. Se realizó medición de 25-hidroxivitamina D total (25[OH]D) en las primeras 48 h del ingreso, parathormona (PTH), calcio, fósforo, gasometría venosa, hemograma, proteína C reactiva y procalcitonina. Se registraron datos sociodemográficos, características del episodio y complicaciones. Resultados: La prevalencia de VDD (< 20ng/ml) fue del 43,8%, con media de 22,28 (IC del 95%, 21,15-23,41) ng/ml. Los pacientes con déficit fueron de mayor edad (61 vs. 47 meses, p = 0,039), sus padres tenían un mayor nivel académico (36,5% vs. 20%, p = 0,016), ingresaron más frecuentemente en invierno y primavera, obtuvieron mayor puntuación PRISM-III (6,8 vs. 5,1, p = 0,037), mayor estancia (3 vs. 2 días, p = 0,001) y morbilidad (61,1% vs. 30,4%, p<0,001) que los pacientes con niveles suficientes (≥ 20ng/ml). Los pacientes fallecidos tuvieron niveles inferiores de 25(OH)D (14 ± 8,81ng/ml vs. 22,53 ± 10,53ng/ml, p = 0,012). La OR ajustada para la morbilidad fue 5,44 (IC del 95%, 2,5-11,6). Conclusiones: El VDD es frecuente en pacientes críticos pediátricos y está relacionado con la morbimortalidad en UCIP, aunque queda por esclarecer si se trata de una relación causal o es simplemente un marcador de gravedad en diferentes situaciones clínicas (AU)

Objectives: To determine the prevalence and risks factors of vitamin D deficiency, as well as its relationship with morbidity and mortality in a PICU. Material and methods An observational prospective study in a tertiary children's University Hospital PICU conducted in two phases: I: cohorts study, and II: prevalence study. The study included 340 critically ill children with ages comprising 6 months to 16 years old. Exclusion criteria: Chronic kidney disease, known parathyroid disorders, and vitamin D supplementation. Total 25-hydroxyvitamin D [25(OH)D] was measured in the first 48 hours of admission to a PICU. Parathormone, calcium, phosphate, blood gases, blood count, C-reactive protein, and procalcitonin were also analysed. A record was also made of demographic features, characteristics of the episode, and complications during the PICU stay. Results: The overall prevalence rate of vitamin D deficiency was 43.8%, with a mean of 22.28 (95% CI 21.15-23.41) ng/ml. Patients with vitamin D deficiency were older (61 vs 47 months, P=.039), had parents with a higher level of academic studies (36.5% vs 20%, P=.016), were admitted more often in winter and spring, had a higher PRISM-III (6.8 vs 5.1, P=.037), a longer PICU stay (3 vs 2 days, P=.001), and higher morbidity (61.1% vs 30.4%, P< 001) than the patients with sufficient levels of 25(OH)D. Patients who died had lower levels of 25(OH)D (14 ± 8.81ng/ml versus 22.53 ± 10.53ng/ml, P=.012). Adjusted OR for morbidity was 5.44 (95%CI; 2.5-11.6). Conclusions: Vitamin D deficiency is frequent in critically ill children, and it is related to both morbidity and mortality, although it remains unclear whether it is a causal relationship or it is simply a marker of severity in different clinical situations (AU)

Hipotiroidismo consuntivo en paciente con hipotiroidismo primario previo / Consumptive hypothyroidism in patient with previous primary hypothyroidism

No disponible

Tratamiento de la hemoglobinuria paroxística nocturna con eculizumab: experiencia en España / Paroxysmal nocturnal hemoglobinuria therapy with eculizumab: Spanish experience

Fundamento y objetivo: La hemoglobinuria paroxística nocturna es una enfermedad clonal adquirida caracterizada por hemólisis mediada por complemento, insuficiencia medular y enfermedad tromboembólica. El eculizumab es un anticuerpo monoclonal dirigido contra la fracción C5 del complemento, que bloquea la formación del componente citolítico de este.Pacientes y método: Se estudian 25 pacientes en tratamiento con eculizumab en España. El análisis estadístico se realiza con el software SPSS v15.0. Resultados:Con una mediana de seguimiento de 14 meses (extremos 3-46), el eculizumab ha conseguido independencia transfusional en 58% de los pacientes y disminución del 60% de los requerimientos transfusionales en el resto de los pacientes, desaparición de la astenia en 96% de los casos y de los síntomas de distonía de músculo liso en la totalidad. Sólo un paciente ha presentado infección grave relacionada con el tratamiento.Conclusiones: El tratamiento con eculizumab es eficaz en el control de la hemólisis, con gran mejoría clínica. El fármaco es seguro y bien tolerado, sin efectos secundarios significativos, salvo el riesgo de infección meningocócica. En pacientes con respuesta subóptima a eculizumab es preciso valorar el grado de insuficiencia medular y la posibilidad de hemólisis extravascular (AU)

Background and objectives: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal disease characterized by complement-mediated hemolysis, bone marrow failure and thrombosis. Eculizumab is a humanized monoclonal antibody that blocks the cytolytic component of the complement system by binding to complement C5. Material and Methods: We report the results of eculizumab treatment in 25 PNH patients from different centers in Spain. Statistical analysis was perfomed with a SPSS v15.0 software.Results: Fifty-eight per cent of the patients achieved transfusional independence after a median of 14 months. Transfusion requirements were reduced in 60% of the remaining cases. Fatigue resolved in 96% of the patients and smooth muscle dystony-related symptoms in all cases. A single case of treatment-related infection was observed. Conclusions: Eculizumab controls effectively hemolysis and greatly improves clinical symptoms. The drug is safe and well tolerated, without significant adverse effects except meningococcal infection. Patients with suboptimal response to treatment must be assessed for bone marrow insufficiency and extravascular haemolysis (AU)

Evaluation of different solvent systems for the extraction and fractionation of oleoresins from guajillo peppers / Evaluación de diferentes solventes para la extracción y fraccionamiento de oleorresinas a partir de chile guajillo

Dried guajillo peppers were first extracte with four different solvents: ethanol, acetone, ethyl acetate and hexane with the aim of obtaining oleoresins which were futher fractionated into red and paprika extracts. Results showed that as the polarity of the solvent increased the amount of pigment extracted also increased. Acetone had good affinity for pungent (capsaicin) compounds. Utilization of these solvents alone did not produce red and paprika oleoresins that meet commercial specifications. Fractionation of acetone extracted oleoresins with ethanol: water (90:10) yielded a precipitate and a solution. The precipitate and solution produced red and paprika extracts that meet pungency and color specifications. It was possible to obtain red and paprika oleoresins from mild guajillo peppers